- ￥100 - 750
- MedChemExpress(MCE)
- 美国
- HY-107319
- 2025年07月13日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
4°C, sealed storage, away from moisture
- 英文名：
Almitrine bismesylate; Almitrine bismethanesulfonate; Almitrine dimesylate
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
29608-49-9
- 规格：
10 mM * 1 mL/5 mg/10 mg/50 mg/100 mg
| 规格： | 10 mM * 1 mL | 产品价格： | ￥165.0 |
|---|---|---|---|
| 规格： | 5 mg | 产品价格： | ￥100.0 |
| 规格： | 10 mg | 产品价格： | ￥150.0 |
| 规格： | 50 mg | 产品价格： | ￥450.0 |
| 规格： | 100 mg | 产品价格： | ￥750.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Almitrine mesylate
CAS No. : 29608-49-9
MCE 国际站：Almitrine mesylate
产品活性：Almitrine mesylate 是一种外周化学感受器的激动剂，选择性抑制 Ca2+依赖性的 K+ 通道。
研究领域：Membrane Transporter/Ion Channel
作用靶点：Potassium Channel
In Vitro: Almitrine inhibits the activity of a high-conductance (152±13 pS), Ca2+-dependent K+ channel by decreasing its open probability. The IC50 value of the effect is 0.22 μM. The inhibitory effect of Almitrine on Ca2+-dependent K+ channels also is observed in GH3 cells. Almitrine at concentrations up to 10 μM does not affect whole-cell voltage-dependent K+, Ca2+, or Na+ currents in rat or rabbit cells. However, this concentration of Almitrine significantly inhibits the Ca2+-dependent component of K+ currents in rat chemoreceptor cells.
In Vivo: Almitrine acts via the peripheral arterial chemoreceptors raising carotid sinus nerve output and minute ventilation. Almitrine also has a pulmonary vascular action causing a dose-dependent constriction and dilatation. At low doses Almitrine enhances hypoxic pulmonary vasoconstriction and may improve the overall ventilation/perfusion ratio.
相关产品：Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Membrane Transporter/Ion Channel Compound Library | FDA-Approved Drug Library | Drug Repurposing Compound Library | Anti-Cardiovascular Disease Compound Library | NMPA-Approved Drug Library | FDA Approved & Pharmacopeial Drug Library | Anti-Alzheimer's Disease Compound Library | Neurodegenerative Disease-related Compound Library | Targeted Diversity Library | Potassium Channel Compound Library | Off-patent Drug Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Highly Selective Inhibitors Library | Ion Channel Compound Library | Nigericin sodium salt | Yoda 1 | BAPTA-AM | Minocycline hydrochloride | Branaplam | Rosuvastatin Calcium | SCH-23390 hydrochloride | Glibenclamide | Quinidine (15% dihydroquinidine) | Tetrandrine | Carbamazepine | 20(S)-Ginsenoside Rg3 | DCPIB | E-4031 | Amiodarone hydrochloride | Minoxidil | TRAM-34 | Tannic acid | (±)-Naringenin | Quinine | Terfenadine | SKF-96365 hydrochloride | Mefloquine hydrochloride | 4-Aminopyridine | GW9508 | PAP-1 | Astemizole | Flufenamic acid | Guanosine 5'-diphosphate disodium salt | Tolbutamide
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Detection of BCR-ABL Mutations and Resistance to Imatinib Mesylate
The major mechanism of imatinib resistance for patients with chronic myeloid leukemia (CML) is clonal expansion of leukemic cells with mutations in the Bcr-Abl fusion tyrosine kinase that reduce the capacity of imatinib to inhibit kinase
-4 and C-5 centers ( 3 ). After formatron of the mesylate, from the recycled material the amine function is introduced through azrde displacement of the mesylate, followed by reduction ( 4 ) and protectron with the t -BOC group. Finally, the lactone
Inhibitors of Cellular Signaling Targets: Designs and Limitations
. Because of their central role in cellular signaling, as well as their primary role in disease progression, protein kinases are attractive therapeutic targets (2 ,3 ). Seven molecules targeting protein kinases, imatinib mesylate (Gleevec) and trastuzumab (Herceptin
技术资料暂无技术资料 索取技术资料
